비감염성 황반부종 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년) - 약물 유형별, 적응증별, 투여 경로별, 유통 채널별, 지역별

Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 7,007,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,917,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,870,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 비감염성 황반부종 치료 시장의 획기적인 발전을 조명하는 획기적인 연구 결과가 나왔습니다. 당뇨병과 관련된 합병증이 급증하고 다양한 지역에서 눈 관련 질환에 대한 인식이 높아지면서 황반부종에 대한 효과적인 치료법에 대한 수요가 급증하고 있습니다. 이러한 수요 증가로 인해 항VEGF제, 부신피질 스테로이드, 면역억제제, 생물학적 제제 등 다양한 치료 옵션이 시장에 등장하고 있습니다. 항VEGF 치료제는 전통적으로 시장을 독점하고 있으며, 예측 기간 동안 높은 시장 점유율을 유지할 것으로 예상됩니다.

그러나 항VEGF 약물 시장은 항VEGF 약물과 관련된 잠재적 부작용에 대한 인식이 높아짐에 따라 점차 사용량이 감소할 것으로 예상됩니다. 전신 면역 조절 치료로 인해 항VEGF제에 대한 의존도는 감소할 것으로 보입니다. 특히 부신피질 스테로이드는 향후 몇 년 동안 수요가 급증할 것으로 예상되며, 예측 기간 동안 시장이 급성장할 것으로 예상됩니다.

최근 황반부종 치료용 유리체강내 임플란트의 승인은 시장 성장의 기폭제가 되고 있으며, Eylea, Ozurdex, Iluvien 등 세 가지 신제품의 출시로 특히 북미에서 유리체강내 주사제 채택이 증가하고 있습니다. 2012년 루센티스가 출시되기 전까지 북미와 유럽 국가에서는 유리체강내 주사제가 많이 사용되지 않았으며, 레이저 광응고요법이 주요 치료법이었습니다.

유리체강내 주사 요법의 채택이 증가하고 있는 이유는 저용량으로 높은 효과를 보이는 코르티코스테로이드 임플란트를 유리체강내 주사로 사용할 수 있게 되었기 때문입니다. 환자들은 점점 더 많은 유리체내 임플란트를 사용하고 있으며, 이는 황반부종 치료에 대한 전 세계 수요를 주도하고 있습니다.

면역 억제 요법은 종종 부신피질 스테로이드와 함께 사용되며, 황반부종 치료에 중요한 역할을 합니다. 이러한 치료제는 일반적으로 코르티코스테로이드 요법에 추가되어 스테로이드의 대량 투여의 필요성을 감소시키거나 스테로이드 치료에 대한 내약성이 충분하지 않은 경우 스테로이드 보존제로 단독으로 사용됩니다.

시장이 큰 성장 잠재력을 보여주고 있는 반면, 도전과제도 남아있습니다. 많은 환자와 안과 의사들이 항VEGF제나 코르티코스테로이드보다 대체 치료법을 선택하고 있습니다. 당뇨병성 황반부종(DME) 환자의 경우, 주사를 놓쳐 치료 일정을 준수하지 않으면 돌이킬 수 없는 손상과 영구적인 시력 손실로 이어질 수 있습니다.

또한, 위조 의약품과 적응증 외 의약품은 전 세계 시장에서 쉽게 구할 수 있습니다. 일부 히트작 항VEGF 약물의 바이오시밀러가 출시됨에 따라 브랜드 약품과 특허 약품의 사용 기회가 줄어들어 시장에 더 많은 영향을 미칠 것으로 예상됩니다.

본 보고서는 세계 비감염성 황반부종 치료 시장에 대해 조사했으며, 시장 개요와 함께 약제 종류별, 적응증별, 투여 경로별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 생산량과 무역 통계, 2018-2023년

제4장 가격 분석, 2018-2023년

제5장 세계의 비감염성 황반부종 치료 시장 전망, 2018-2031년

• 세계의 비감염성 황반부종 치료 시장 전망, 약제 유형별, 금액(100만 달러), 수량(2018-2031년)
• 세계의 비감염성 황반부종 치료 시장 전망, 적응증별, 금액(100만 달러), 수량(2018-2031년)
• 세계의 비감염성 황반부종 치료 시장 전망, 투여 경로, 금액(100만 달러), 수량(2018-2031년)
• 세계의 비감염성 황반부종 치료 시장 전망, 유통 채널별, 금액(100만 달러), 수량(2018-2031년)
• 세계의 비감염성 황반부종 치료 시장 전망, 지역별, 금액(100만 달러), 수량(2018-2031년)

제6장 북미의 비감염성 황반부종 치료 시장 전망, 2018-2031년

제7장 유럽의 비감염성 황반부종 치료 시장 전망, 2018-2031년

제8장 아시아태평양의 비감염성 황반부종 치료 시장 전망, 2018-2031년

제9장 라틴아메리카의 비감염성 황반부종 치료 시장 전망, 2018-2031년

제10장 중동 및 아프리카의 비감염성 황반부종 치료 시장 전망, 2018-2031년

제11장 경쟁 상황

• 제품과 적응증 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc
  • Bayer AG
  • Valeant Pharmaceuticals Inc
  • Alimera Sciences Inc
  • Clearside Biomedical, Inc

제12장 부록

ksm

영문 목차

영문목차

A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products - Eylea, Ozurdex, and Iluvien - has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators - methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) - have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type

• Anti-VEGF
• Corticosteroids
• Immunosuppressant
• Biologics
• Others

Indication

• Non-infectious Uveitic Macular Edema
• Diabetic Macular Edema
• Retinal Vein Occlusion with Macular Edema

Route of Administration

• Oral
• Parenteral
• Topical

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Latin America
• Europe
• Japan
• MEA
• APAC

Table of Contents

1. Executive Summary

• 1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value and Volume, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

• 3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
  • 3.1.1. North America
  • 3.1.2. Europe
  • 3.1.3. Asia Pacific
  • 3.1.4. Latin America
  • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

• 4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
• 4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
• 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Anti-VEGF
    • 5.1.1.2. Corticosteroids
    • 5.1.1.3. Immunosuppressant
    • 5.1.1.4. Biologics
    • 5.1.1.5. Others
• 5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Non-infectious Uveitic Macular Edema
    • 5.2.1.2. Diabetic Macular Edema
    • 5.2.1.3. Retinal Vein Occlusion with Macular Edema
• 5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Oral
    • 5.3.1.2. Parenteral
    • 5.3.1.3. Topical
• 5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospital Pharmacies
    • 5.4.1.2. Retail Pharmacies
    • 5.4.1.3. Online Pharmacies
• 5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
  • 5.5.1. Key Highlights
    • 5.5.1.1. North America
    • 5.5.1.2. Europe
    • 5.5.1.3. Asia Pacific
    • 5.5.1.4. Latin America
    • 5.5.1.5. Middle East & Africa

6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Anti-VEGF
    • 6.1.1.2. Corticosteroids
    • 6.1.1.3. Immunosuppressant
    • 6.1.1.4. Biologics
    • 6.1.1.5. Others
• 6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Non-infectious Uveitic Macular Edema
    • 6.2.1.2. Diabetic Macular Edema
    • 6.2.1.3. Retinal Vein Occlusion with Macular Edema
• 6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Oral
    • 6.3.1.2. Parenteral
    • 6.3.1.3. Topical
• 6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospital Pharmacies
    • 6.4.1.2. Retail Pharmacies
    • 6.4.1.3. Online Pharmacies
• 6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.5.1. Key Highlights
    • 6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Anti-VEGF
    • 7.1.1.2. Corticosteroids
    • 7.1.1.3. Immunosuppressant
    • 7.1.1.4. Biologics
    • 7.1.1.5. Others
• 7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Non-infectious Uveitic Macular Edema
    • 7.2.1.2. Diabetic Macular Edema
    • 7.2.1.3. Retinal Vein Occlusion with Macular Edema
• 7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Oral
    • 7.3.1.2. Parenteral
    • 7.3.1.3. Topical
• 7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospital Pharmacies
    • 7.4.1.2. Retail Pharmacies
    • 7.4.1.3. Online Pharmacies
• 7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.5.1. Key Highlights
    • 7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Anti-VEGF
    • 8.1.1.2. Corticosteroids
    • 8.1.1.3. Immunosuppressant
    • 8.1.1.4. Biologics
    • 8.1.1.5. Others
• 8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Non-infectious Uveitic Macular Edema
    • 8.2.1.2. Diabetic Macular Edema
    • 8.2.1.3. Retinal Vein Occlusion with Macular Edema
• 8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Oral
    • 8.3.1.2. Parenteral
    • 8.3.1.3. Topical
• 8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospital Pharmacies
    • 8.4.1.2. Retail Pharmacies
    • 8.4.1.3. Online Pharmacies
• 8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.5.1. Key Highlights
    • 8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.1.1. Key Highlights
    • 9.1.1.1. Anti-VEGF
    • 9.1.1.2. Corticosteroids
    • 9.1.1.3. Immunosuppressant
    • 9.1.1.4. Biologics
    • 9.1.1.5. Others
• 9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.2.1. Key Highlights
    • 9.2.1.1. Non-infectious Uveitic Macular Edema
    • 9.2.1.2. Diabetic Macular Edema
    • 9.2.1.3. Retinal Vein Occlusion with Macular Edema
• 9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.3.1. Key Highlights
    • 9.3.1.1. Oral
    • 9.3.1.2. Parenteral
    • 9.3.1.3. Topical
• 9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.4.1. Key Highlights
    • 9.4.1.1. Hospital Pharmacies
    • 9.4.1.2. Retail Pharmacies
    • 9.4.1.3. Online Pharmacies
• 9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.5.1. Key Highlights
    • 9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

• 10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.1.1. Key Highlights
    • 10.1.1.1. Anti-VEGF
    • 10.1.1.2. Corticosteroids
    • 10.1.1.3. Immunosuppressant
    • 10.1.1.4. Biologics
    • 10.1.1.5. Others
• 10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.2.1. Key Highlights
    • 10.2.1.1. Non-infectious Uveitic Macular Edema
    • 10.2.1.2. Diabetic Macular Edema
    • 10.2.1.3. Retinal Vein Occlusion with Macular Edema
• 10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.3.1. Key Highlights
    • 10.3.1.1. Oral
    • 10.3.1.2. Parenteral
    • 10.3.1.3. Topical
• 10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.4.1. Key Highlights
    • 10.4.1.1. Hospital Pharmacies
    • 10.4.1.2. Retail Pharmacies
    • 10.4.1.3. Online Pharmacies
• 10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.5.1. Key Highlights
    • 10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

• 11.1. Product vs Indication Heatmap
• 11.2. Company Market Share Analysis, 2023
• 11.3. Competitive Dashboard
• 11.4. Company Profiles
  • 11.4.1. Pfizer, Inc.
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Product Portfolio
    • 11.4.1.3. Financial Overview
    • 11.4.1.4. Business Strategies and Development
  • 11.4.2. Novartis AG
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Product Portfolio
    • 11.4.2.3. Financial Overview
    • 11.4.2.4. Business Strategies and Development
  • 11.4.3. F. Hoffman - La Roche Ltd.
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Product Portfolio
    • 11.4.3.3. Financial Overview
    • 11.4.3.4. Business Strategies and Development
  • 11.4.4. AbbVie Inc
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Product Portfolio
    • 11.4.4.3. Financial Overview
    • 11.4.4.4. Business Strategies and Development
  • 11.4.5. Bayer AG
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Product Portfolio
    • 11.4.5.3. Financial Overview
    • 11.4.5.4. Business Strategies and Development
  • 11.4.6. Valeant Pharmaceuticals Inc
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Product Portfolio
    • 11.4.6.3. Financial Overview
    • 11.4.6.4. Business Strategies and Development
  • 11.4.7. Alimera Sciences Inc
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Product Portfolio
    • 11.4.7.3. Financial Overview
    • 11.4.7.4. Business Strategies and Development
  • 11.4.8. Clearside Biomedical, Inc
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Product Portfolio
    • 11.4.8.3. Financial Overview
    • 11.4.8.4. Business Strategies and Development

12. Appendix

• 12.1. Research Methodology
• 12.2. Report Assumptions
• 12.3. Acronyms and Abbreviations

관련자료